Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Acumen Pharmaceuticals Inc.

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals, with a price target of $4.00. Shrader c...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABOS	$2.14	+9.18%	274.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABOS	$2.14	+9.2%	274.13K
3
4
5
6

ABOS

ABOS

Dividend Overview

Get Acumen Pharmaceuticals Inc. Data in Excel

Get Acumen Pharmaceuticals Inc. Data in Excel